Chromadex Corp (CDXC) Shares Sold by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC cut its stake in shares of Chromadex Corp (OTCMKTS:CDXC) by 3.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 81,255 shares of the company’s stock after selling 2,794 shares during the period. TIAA CREF Investment Management LLC’s holdings in Chromadex Corp were worth $219,000 at the end of the most recent quarter.
Separately, Tieton Capital Management LLC bought a new position in Chromadex Corp during the first quarter valued at $1,853,000.
Shares of Chromadex Corp (OTCMKTS CDXC) traded up 3.03% during midday trading on Thursday, hitting $3.40. The stock had a trading volume of 85,817 shares. The company’s 50-day moving average price is $3.37 and its 200-day moving average price is $3.12. Chromadex Corp has a 12-month low of $2.25 and a 12-month high of $4.19. The firm’s market cap is $156.72 million.
Chromadex Corp (OTCMKTS:CDXC) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by $0.09. The firm had revenue of $5.31 million for the quarter, compared to the consensus estimate of $11 million. Chromadex Corp had a negative return on equity of 79.98% and a negative net margin of 43.35%. Equities research analysts forecast that Chromadex Corp will post ($0.14) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Chromadex Corp (CDXC) Shares Sold by TIAA CREF Investment Management LLC” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/chromadex-corp-cdxc-shares-sold-by-tiaa-cref-investment-management-llc/1534425.html.
Several equities analysts have weighed in on the company. ValuEngine downgraded Chromadex Corp from a “hold” rating to a “sell” rating in a research report on Friday, June 30th. HC Wainwright set a $5.00 price target on Chromadex Corp and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, Zacks Investment Research downgraded Chromadex Corp from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.
In related news, major shareholder Step Holdings Ltd Pioneer acquired 786,167 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The shares were acquired at an average cost of $2.60 per share, with a total value of $2,044,034.20. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Robert N. Fried acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was bought at an average cost of $3.15 per share, for a total transaction of $31,500.00. Following the completion of the transaction, the insider now directly owns 583,241 shares in the company, valued at approximately $1,837,209.15. The disclosure for this purchase can be found here. Insiders purchased a total of 798,167 shares of company stock worth $2,082,154 over the last ninety days.
About Chromadex Corp
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chromadex Corp (OTCMKTS:CDXC).
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.